HER2-positive breast cancer trials recruiting in New York

All HER2-positive breast cancer trials nationally

Cities in New York

Recruiting trials in New York

• A Phase 1/1b Study of IAM1363 in HER2 Cancers
  NCT06253871 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
  NCT07102381 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Camillus, New York
• A Study of Surgery and Radiotherapy in People With Breast Cancer
  NCT07053085 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Rockville Centre
• HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
  NCT07459673 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Commack, Harrison, New York, Uniondale
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
  NCT01042379 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo, New York, Rochester, The Bronx
• Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
  NCT06220214 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: Female · New York: Stony Brook
• RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
  NCT07413939 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Albany, Shirley
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · New York: New York
• Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
  NCT04886531 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Rochester